SK15112002A3 - Liečivo na liečenie sexuálnej dysfunkcie pacienta - Google Patents

Liečivo na liečenie sexuálnej dysfunkcie pacienta Download PDF

Info

Publication number
SK15112002A3
SK15112002A3 SK1511-2002A SK15112002A SK15112002A3 SK 15112002 A3 SK15112002 A3 SK 15112002A3 SK 15112002 A SK15112002 A SK 15112002A SK 15112002 A3 SK15112002 A3 SK 15112002A3
Authority
SK
Slovakia
Prior art keywords
apomorphine
administration
drug
sexual dysfunction
oral
Prior art date
Application number
SK1511-2002A
Other languages
English (en)
Slovak (sk)
Inventor
Pramod K. Gupta
John Daniel Bollinger
Yisheng Chen
Jack Yuqun Zheng
Thomas L. Reiland
Dennis Y. Lee
Original Assignee
Tap Pharmaceutical Products Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tap Pharmaceutical Products Inc. filed Critical Tap Pharmaceutical Products Inc.
Publication of SK15112002A3 publication Critical patent/SK15112002A3/sk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A61P5/12—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH for decreasing, blocking or antagonising the activity of the posterior pituitary hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Otolaryngology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
SK1511-2002A 2000-03-20 2001-03-14 Liečivo na liečenie sexuálnej dysfunkcie pacienta SK15112002A3 (sk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US19054000P 2000-03-20 2000-03-20
PCT/US2001/040294 WO2001074358A1 (en) 2000-03-20 2001-03-14 Methods for treating sexual dysfunction with apomorphine at specified plasma concentration levels

Publications (1)

Publication Number Publication Date
SK15112002A3 true SK15112002A3 (sk) 2003-06-03

Family

ID=22701756

Family Applications (1)

Application Number Title Priority Date Filing Date
SK1511-2002A SK15112002A3 (sk) 2000-03-20 2001-03-14 Liečivo na liečenie sexuálnej dysfunkcie pacienta

Country Status (18)

Country Link
US (1) US20020006933A1 (es)
EP (1) EP1265609A4 (es)
JP (1) JP2003533441A (es)
KR (1) KR20030012852A (es)
CN (1) CN1315177A (es)
AU (1) AU2001253854A1 (es)
BG (1) BG107185A (es)
BR (1) BR0005797A (es)
CA (1) CA2403791A1 (es)
CZ (1) CZ20023427A3 (es)
HU (1) HUP0301828A3 (es)
IL (1) IL151615A0 (es)
MX (1) MXPA02009237A (es)
NO (1) NO20024442L (es)
PL (1) PL365854A1 (es)
SK (1) SK15112002A3 (es)
WO (1) WO2001074358A1 (es)
ZA (1) ZA200207113B (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6566368B2 (en) * 1994-04-22 2003-05-20 Pentech Pharmaceuticals, Inc. Apomorphine-containing dosage form for ameliorating male erectile dysfunction
SE0102036D0 (sv) * 2001-06-08 2001-06-08 Axon Biochemicals Bv Pharmaceutical formulation for the efficient administration of apomorphine, 6aR- (-) -N- Propyl- norapomorphine and their derivatives and pro-drugs thereof
AR032556A1 (es) * 2001-02-08 2003-11-12 Pharmacia Corp Medicamento de accion inmediata para el tratamiento de la disfuncion sexual
EP1340492A1 (en) * 2002-03-01 2003-09-03 CHIESI FARMACEUTICI S.p.A. Aerosol formulations for pulmonary administration of medicaments having systemic effects
US20040018237A1 (en) * 2002-05-31 2004-01-29 Perricone Nicholas V. Topical drug delivery using phosphatidylcholine
WO2004078211A1 (ja) * 2003-03-04 2004-09-16 Tanabe Seiyaku Co., Ltd. 粉末経鼻投与製剤
US20040204439A1 (en) * 2003-04-14 2004-10-14 Staniforth John Nicholas Composition, device, and method for treating sexual dysfunction via inhalation
US20060147389A1 (en) * 2004-04-14 2006-07-06 Vectura Ltd. Devices and pharmaceutical compositions for enhancing dosing efficiency
WO2004089374A1 (en) * 2003-04-14 2004-10-21 Vectura Ltd Pharmaceutical compositions comprising apomorphine for pulmonary inhalation
GB0604319D0 (en) * 2006-03-03 2006-04-12 Optinose As Nasal delivery
GB2437488A (en) * 2006-04-25 2007-10-31 Optinose As Pharmaceutical oily formulation for nasal or buccal administration
GB0721394D0 (en) * 2007-10-31 2007-12-12 Vectura Group Plc Compositions for trating parkinson's disease
EP3735988A1 (en) 2010-12-16 2020-11-11 Sunovion Pharmaceuticals Inc. Sublingual films
EP2545905A1 (en) * 2011-07-11 2013-01-16 Britannia Pharmaceuticals Limited A new therapeutical composition containing apomorphine as active ingredient
BR112014030265A2 (pt) * 2012-06-05 2017-06-27 Neuroderm Ltd composição farmacêutica líquida ou semissólida e método para tratar uma doença ou distúrbio neurológico ou de movimento.
WO2014205031A1 (en) * 2013-06-19 2014-12-24 Map Pharmaceuticals, Inc. Sustained-release formulation of rotigotine

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5472954A (en) * 1992-07-14 1995-12-05 Cyclops H.F. Cyclodextrin complexation
DE4321965A1 (de) * 1993-07-01 1995-01-12 Cytech Biomedical Inc Oxytocin-haltige Zusammensetzung sowie die Verwendung derselben als Mittel, insbesondere Nasenspray zur Behandlung sexueller Dysfunktionen
CA2312839C (en) * 1997-12-02 2008-01-15 Lisbeth Illum Compositions for nasal administration
US5945117A (en) * 1998-01-30 1999-08-31 Pentech Pharmaceuticals, Inc. Treatment of female sexual dysfunction
JP2002518435A (ja) * 1998-06-22 2002-06-25 クイーンズ ユニバーシティ アット キングストン 女性の性機能不全の治療または改善のための方法および組成物
US6436950B1 (en) * 1998-08-14 2002-08-20 Nastech Pharmaceutical Company, Inc. Nasal delivery of apomorphine
US5994363A (en) * 1998-08-24 1999-11-30 Pentech Pharmaceuticals, Inc. Amelioration of apomorphine adverse effects
US6291471B1 (en) * 1998-12-17 2001-09-18 Abb Holdings, Inc. Use of apomorphine for the treatment of organic erectile dysfunction in males

Also Published As

Publication number Publication date
AU2001253854A1 (en) 2001-10-15
US20020006933A1 (en) 2002-01-17
CZ20023427A3 (cs) 2003-11-12
HUP0301828A2 (hu) 2003-09-29
JP2003533441A (ja) 2003-11-11
CA2403791A1 (en) 2001-10-11
BG107185A (bg) 2003-05-30
BR0005797A (pt) 2001-10-16
CN1315177A (zh) 2001-10-03
KR20030012852A (ko) 2003-02-12
HUP0301828A3 (en) 2006-02-28
NO20024442L (no) 2002-11-20
EP1265609A4 (en) 2005-02-09
IL151615A0 (en) 2003-04-10
ZA200207113B (en) 2004-01-28
MXPA02009237A (es) 2004-04-05
WO2001074358A1 (en) 2001-10-11
NO20024442D0 (no) 2002-09-17
PL365854A1 (en) 2005-01-10
EP1265609A1 (en) 2002-12-18

Similar Documents

Publication Publication Date Title
SK15112002A3 (sk) Liečivo na liečenie sexuálnej dysfunkcie pacienta
US5030645A (en) Method of treating asthma using (S)-α-fluoromethyl-histidine and esters thereof
US20090239881A1 (en) Combinations of Flibanserin with Caffeine, Process for Their Preparation and Use Thereof as Medicaments
CZ20023637A3 (cs) Deriváty apomorfinu a způsoby jejich použití
SK285990B6 (sk) Kombinácia nesedatívnych antihistaminík so substanciami, ktoré ovplyvňujú pôsobenie leukotriénu, naošetrovanie rinitídy/konjunktivitídy
US6528521B2 (en) Treatment of anti-depression drug-induced sexual dysfunction with apomorphine
EP4041274B1 (en) Ws-635 for use in the treatment of postoperative cognitive dysfunction
SK12682003A3 (sk) Prípravky obsahujúce imidazotriazinón na nazálnu aplikáciu
AU2005231479A1 (en) (R,R)-formoterol in combination with other pharmacological agents
US20240024293A1 (en) Nomethiazoles as a treatment for rett syndrome
US20020086876A1 (en) Treatment of anti-depression drug-induced sexual dysfunction with apomorphine
KR20210131996A (ko) 과다복용 및 보상-기반 장애의 치료를 위한 조성물, 장치 및 방법
US7842702B2 (en) Treatment for irritable bowel syndrome
EA042299B1 (ru) Фармацевтические композиции и их применения
JPWO2005011674A1 (ja) 気管支喘息の予防及び／または治療剤

Legal Events

Date Code Title Description
FC9A Refused patent application